VolitionRx Limited to Attend Multiple Conferences in September

Download PDF

ISNES, Belgium, Sept. 6, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) today announced that its Chief Executive Officer, Cameron Reynolds, its Executive Vice President, Scott Powell, and/or its Chief Medical Officer, Dr. Jason Terrell, are scheduled to attend and present at multiple conferences in September.

During their presentations, management will outline Volition's business, clinical, regulatory and operational milestones, as well as the Company's recently announced U.S. clinical trial with the National Cancer Institute's Early Detection Research Network (EDRN).

Details of the conferences are as follows:

Conference:

Rodman & Renshaw 19th Annual Global Investment Conference

Date:

Tuesday, September 12, 2017

Time:

3:50 p.m. EDT

Location:

Lotte New York Palace Hotel, New York, NY



Conference:

MicroCap Leadership Summit

Date:

Friday, September 22, 2017

Time:

8:30 a.m.–5:00 p.m. CDT (Small Group Presentations)

Location:

Westin Chicago Northwest Hotel, Itasca, IL



Conference:

Rocky Mountain MicroCap Conference

Date:

Monday, September 25, 2017

Time:

TBD

Location:

Coors Field, Denver, CO



Conference:

Ladenburg Thalmann 2017 Healthcare Conference

Date:

Tuesday, September 26, 2017

Time:

3:30 p.m. EDT

Location:

Sofitel Hotel, New York, NY   



Conference:

Cantor Fitzgerald Global Healthcare Conference

Date:

Wednesday, September 27, 2017

Time:

8:00 a.m. EDT

Location:

InterContinental New York Barclay Hotel, New York, NY   



Conference:

2017 Disruptive Growth Company Showcase NYC

Date:

Wednesday, September 27, 2017

Time:

TBD

Location:

Grand Hyatt Grand Central Hotel, New York, NY   



Conference:

Sidoti & Company Fall 2017 Conference

Date:

Thursday, September 28, 2017

Time:

1:20 p.m. EDT

Location:

Marriott Marquis Hotel, New York, NY



Conference:

18th Annual GCFF Toronto Conference 2017

Date:

Saturday, September 30, 2017

Time:

TBD

Location:

Courtyard Toronto Northeast/Markham, Markham, ON

Persons attending any of the above-referenced conferences who would like to schedule a 1-on-1 meeting with Volition management during such conference may do so by contacting Tirth Patel of Edison Advisors at tpatel@edisongroup.com  or Scott Powell, Executive Vice President, at S.Powell@volitionrx.com.  

About Volition

Volition is a multi-national life sciences company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers. The tests are based on the science of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid -- an indication that disease is present.

As cancer screening programs become more widespread, Volition's products aim to help to diagnose a range of cancers quickly, simply, accurately and cost effectively. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life.

Volition's research and development activities are currently centered in Belgium, with additional offices in London, Texas and Singapore, as the company focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and ultimately, worldwide.

For more information about Volition, visit Volition's website (http://www.volitionrx.com) or connect with us via:

Twitter: https://twitter.com/volitionrx 
LinkedIn: https://www.linkedin.com/company/volitionrx 
Facebook: https://www.facebook.com/VolitionRx/ 
YouTube: https://www.youtube.com/user/VolitionRx

The contents found at Volition's website address, Twitter, LinkedIn, Facebook, and YouTube are not incorporated by reference into this document and should not be considered part of this document.  The addresses for Volition's website, Twitter, LinkedIn, Facebook, and YouTube are included in this document as inactive textual references only.

Media / Investor Contacts

Louise Day, Volition

L.day@volitionrx.com

+44 (0)7557 774620

Scott Powell, Volition

S.powell@volitionrx.com

+1 (646) 650 1351

Tirth Patel, Edison Advisors

tpatel@edisongroup.com

+1 (646) 653 7035

Rachel Carroll, Edison Advisors

rcarroll@edisongroup.com

+44 (0)20 3077 5711

Nucleosomics®, NuQ®, Nu.QTM and HyperGenomics® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners.

View original content:http://www.prnewswire.com/news-releases/volitionrx-limited-to-attend-multiple-conferences-in-september-300514833.html

SOURCE VolitionRx Ltd

arrow-down arrow-left arrow-right arrow chevron-down circle-link--red circle-link close play plus